ERA

Download the full-sized PDF of Identification of Chemical Correctors for the Trafficking Defect of Mutant SLC4A11Download the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R32Z12V6F

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

Identification of Chemical Correctors for the Trafficking Defect of Mutant SLC4A11 Open Access

Descriptions

Other title
Subject/Keyword
Dystrophy
Highthroughput
SLC4A11
Rescue
Cornea
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Chiu, Anthony M.
Supervisor and department
Casey, Joseph (Biochemistry, Physiology)
Examining committee member and department
Cordat, Emmanuelle (Physiology)
Lehmann, Ordan (Ophthalmology and Visual Sciences, Medical Genetics)
Leslie, Elaine (Physiology)
Department
Department of Physiology
Specialization

Date accepted
2015-08-13T10:04:14Z
Graduation date
2015-11
Degree
Master of Science
Degree level
Master's
Abstract
Congenital Hereditary Endothelial Dystrophy, Harboyan Syndrome and Fuchs’ Endothelial Corneal Dystrophy are three forms of heterogeneous, genetic corneal blindness. Mutations in the membrane protein SLC4A11 have been found to cause cases of these diseases. Most mutations in SLC4A11 cause the protein to misfold and become retained in the endoplasmic reticulum. The loss of function of SLC4A11 is thought to give rise to the symptoms of these diseases. Currently, the only permanent therapy for these diseases is corneal transplant. A pharmacological therapy is needed to better treat these diseases caused by SLC4A11. Screening techniques for the assessment of small molecule correctors is the first step toward a pharmacological therapy. A high throughput screening assay was developed to detect SLC4A11 at the plasma membrane. This technique could also be applied to other plasma membrane proteins. A small scale screen revealed that three non-steroidal anti-inflammatory drugs rescue the trafficking defect of some mutations of SLC4A11. Glafenine was effective in rescuing the trafficking defect in all three mutations screened. Functional analysis revealed that these mutants, when rescued to the plasma membrane, retained functional activity. These data suggest that glafenine may be a viable therapeutic for some cases of endothelial corneal dystrophies.
Language
English
DOI
doi:10.7939/R32Z12V6F
Rights
Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. The author reserves all other publication and other rights in association with the copyright in the thesis and, except as herein before provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication

File Details

Date Uploaded
Date Modified
2015-08-13T16:04:15.548+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (PDF/A)
Mime type: application/pdf
File size: 2195657
Last modified: 2016:06:24 18:38:40-06:00
Filename: Chiu_Anthony_MBK_201507_MSc.pdf
Original checksum: 7da3e92c513ed460b1a6ac488a5e6716
Activity of users you follow
User Activity Date